Ellabban, 2017 - Google Patents

The Role of RGMa/Neogenin Signaling in Experimental Autoimmune Encephalomyelitis

Ellabban, 2017

View PDF
Document ID
11007140752185735674
Author
Ellabban A
Publication year

External Links

Snippet

Abstract Repulsive Guidance Molecule A (RGMa) and its receptor, Neogenin, have been reported to play an important role in the developing chick visual system. More recently, RGMa have been implicated in playing a crucial role in the development of Experimental …
Continue reading at dam-oclc.bac-lac.gc.ca (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
US11926671B2 (en) Antibodies and polypeptides directed against CD127
TWI845803B (en) Anti-ccr8 antibodies and uses thereof
US20220056128A1 (en) Anti-lilrb2 antibodies and methods of use thereof
JP2021520830A (en) Fusion proteins that bind to the CD47 protein and their use
US12083163B2 (en) Isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases
WO2014209802A1 (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
CN109414500A (en) Treatment and diagnosis PD-L1 monoclonal antibody specific
TW201307385A (en) Treatment of gastrointestinal inflammation and psoriasis and asthma
WO2019152516A1 (en) Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN112851819B (en) Bispecific antibody combined with mouse PD-L1 and TGF-beta, and preparation method and application thereof
Ellabban The Role of RGMa/Neogenin Signaling in Experimental Autoimmune Encephalomyelitis
KR20230135556A (en) Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
US11406686B2 (en) Methods for the treatment of tissue lesions with CCR2 agonists
Eissa et al. Neuroimmune mechanisms of cerebellar development and its developmental disorders: Bidirectional link between the immune system and nervous system
RU2828590C2 (en) Immunodominant proteins and fragments in multiple sclerosis
Ricci The role of T cells in the chronic phase after stroke
Reiter et al. Antigen-Specific modulation of MS/EAE by TCR-like Antibody Targeting Auto-Reactive Epitope
Gharagozloo The NOD-Like Receptors as Endogenous Inhibitors of Multiple Sclerosis
Manenti Neutrofili regolatori in neuroinfiammazione
Lee B Cell Responses in an Animal Model of Neuroinflammation: Implications for Multiple Sclerosis
TW202438531A (en) Anti-ccr8 antibodies and uses thereof
EA041126B1 (en) ANTIBODIES AND POLYPEPTIDES AGAINST CD127
JP2022180487A (en) Agent for treatment or prevention of htlv-1-associated myelopathy (ham), and ham treatment method
Karim Estrogen Receptor Beta Ligands Exert Pro-Myelinating Effects by Altering Pro-Inflammatory Responses in an Animal Model of Multiple Sclerosis
Hemmer et al. Immunopathogenesis of multiple sclerosis